BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1160 related articles for article (PubMed ID: 17721369)

  • 21. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).
    American Academy of Pediatrics Committee on Infectious Diseases
    Pediatrics; 2010 Jul; 126(1):186-90. PubMed ID: 20498180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal western Australians from 1997 through 2007 and emergence of nonvaccine serotypes.
    Lehmann D; Willis J; Moore HC; Giele C; Murphy D; Keil AD; Harrison C; Bayley K; Watson M; Richmond P
    Clin Infect Dis; 2010 Jun; 50(11):1477-86. PubMed ID: 20420501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolving picture of invasive pneumococcal disease in massachusetts children: a comparison of disease in 2007-2009 with earlier periods.
    Yildirim I; Stevenson A; Hsu KK; Pelton SI
    Pediatr Infect Dis J; 2012 Oct; 31(10):1016-21. PubMed ID: 22673142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema.
    Byington CL; Korgenski K; Daly J; Ampofo K; Pavia A; Mason EO
    Pediatr Infect Dis J; 2006 Mar; 25(3):250-4. PubMed ID: 16511389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine.
    Halasa NB; Shankar SM; Talbot TR; Arbogast PG; Mitchel EF; Wang WC; Schaffner W; Craig AS; Griffin MR
    Clin Infect Dis; 2007 Jun; 44(11):1428-33. PubMed ID: 17479937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany.
    Rückinger S; van der Linden M; Reinert RR; von Kries R; Burckhardt F; Siedler A
    Vaccine; 2009 Jun; 27(31):4136-41. PubMed ID: 19406190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Invasive pneumococcal disease in Alaskan children: impact of the seven-valent pneumococcal conjugate vaccine and the role of water supply.
    Wenger JD; Zulz T; Bruden D; Singleton R; Bruce MG; Bulkow L; Parks D; Rudolph K; Hurlburt D; Ritter T; Klejka J; Hennessy T
    Pediatr Infect Dis J; 2010 Mar; 29(3):251-6. PubMed ID: 19952861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States.
    Rosen JB; Thomas AR; Lexau CA; Reingold A; Hadler JL; Harrison LH; Bennett NM; Schaffner W; Farley MM; Beall BW; Moore MR;
    Clin Infect Dis; 2011 Jul; 53(2):137-43. PubMed ID: 21690620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case-control study.
    Barricarte A; Castilla J; Gil-Setas A; Torroba L; Navarro-Alonso JA; Irisarri F; Arriazu M
    Clin Infect Dis; 2007 Jun; 44(11):1436-41. PubMed ID: 17479939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):253-7. PubMed ID: 20224541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway.
    Vestrheim DF; Løvoll O; Aaberge IS; Caugant DA; Høiby EA; Bakke H; Bergsaker MR
    Vaccine; 2008 Jun; 26(26):3277-81. PubMed ID: 18456376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nearly complete elimination of the 7-valent pneumococcal conjugate vaccine serotypes in Tennessee.
    Halasa NB; Grijalva CG; Arbogast PG; Talbot TR; Craig AS; Griffin MR; Schaffner W
    Pediatr Infect Dis J; 2013 Jun; 32(6):604-9. PubMed ID: 23348816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Invasive pneumococcal disease and 13-valent pneumococcal conjugate vaccine (PCV13) coverage among children aged ≤59 months---selected U.S. regions, 2010--2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Nov; 60(43):1477-81. PubMed ID: 22048728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2005 Sep; 54(36):893-7. PubMed ID: 16163262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines.
    Shouval DS; Greenberg D; Givon-Lavi N; Porat N; Dagan R
    Pediatr Infect Dis J; 2009 Apr; 28(4):277-82. PubMed ID: 19258924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Invasive pneumococcal disease in Danish children, 1996-2007, prior to the introduction of heptavalent pneumococcal conjugate vaccine.
    Winther TN; Kristensen TD; Kaltoft MS; Konradsen HB; Knudsen JD; Høgh B
    Acta Paediatr; 2009 Feb; 98(2):328-31. PubMed ID: 18983440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eradication of invasive pneumococcal disease due to the seven-valent pneumococcal conjugate vaccine serotypes in Calgary, Alberta.
    Leal J; Vanderkooi OG; Church DL; Macdonald J; Tyrrell GJ; Kellner JD
    Pediatr Infect Dis J; 2012 Sep; 31(9):e169-75. PubMed ID: 22673137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme.
    Ingels H; Rasmussen J; Andersen PH; Harboe ZB; Glismann S; Konradsen H; Hoffmann S; Valentiner-Branth P; Lambertsen L;
    Vaccine; 2012 Jun; 30(26):3944-50. PubMed ID: 22504662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of pneumococcal conjugate vaccines on burden of invasive pneumococcal disease and serotype distribution of Streptococcus pneumoniae isolates: an overview from Kuwait.
    Mokaddas E; Albert MJ
    Vaccine; 2012 Dec; 30 Suppl 6():G37-40. PubMed ID: 23228356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population-based surveillance for invasive pneumococcal disease and pneumonia in infants and young children in Bogotá, Colombia.
    Benavides JA; Ovalle OO; Salvador GR; Gray S; Isaacman D; Rodgers GL
    Vaccine; 2012 Aug; 30(40):5886-92. PubMed ID: 22484295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.